Ascentage Pharma (AAPG) Director Discloses Initial Equity Position
ASCENTAGE PHARMA GROUP INTERNATIONAL
Subscribe to track AAPG
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Ascentage Pharma (AAPG) Director Discloses Initial Equity Position
Company: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form: 3 (Initial Statement) | Filed: 2026/03/19 Significance: Low
Insider: Bozilenko Marina Title: N/A | Relationship: Director
Holdings Disclosed: • Security: Options & RSUs • Total Underlying Shares: 117,790 • Option Strike: $8.14 (53,895 shares) • RSUs: 63,895 shares
Key Insight: New Director disclosure revealing equity compensation package consisting of stock options and restricted stock units vesting through 2029.
Market Context: Procedural filing establishing the baseline ownership for a new board member; represents <0.1% of shares outstanding.
Comprehensive Analysis
SEC Filing Analysis: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Executive Summary
- Trading Significance: Low
- Key Takeaway: New Director Marina Bozilenko establishes initial beneficial ownership reporting equity incentives.
- Market Impact: Neutral; this is a procedural disclosure for a company insider.
Company Information
| Field | Value |
|---|---|
| Company | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| Ticker Symbol | AAPG |
| CIK | 0002023311 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Bozilenko Marina |
| CIK | 0001853794 |
| Title/Position | N/A |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 3 (Initial Statement of Beneficial Ownership) |
| Transaction Date | 2026-03-18 |
| Security Type | Derivative Securities (Options & RSUs) |
| Total Underlying Shares | 117,790 |
| Option Exercise Price | $8.14 (for 53,895 shares) |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Market Cap | $17.49 Billion |
| Shares Outstanding | 373,320,000 |
| Total Holdings Reported | 117,790 shares |
| % of Shares Outstanding | 0.03% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market cap of $17.49B, this initial holding disclosure is financially immaterial to the broader market.
- Ownership Concentration: The director holds approximately 0.03% of the company on a fully diluted basis regarding these specific grants.
- Dilution Impact: The 117,790 underlying shares represent negligible potential dilution (<0.1%).
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Form 3 filings are administrative requirements for new insiders and do not represent open market buying or selling pressure.
Volume & Sentiment
- Expected Volume Impact: None.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Vesting: Both the Options and RSUs vest in four equal increments annually starting 11/26/2026 through 2029.
- Currency: Option exercise price is converted from HKD to USD based on the grant date exchange rate.
- Nature of Holdings: The disclosure consists entirely of derivative securities (Options and RSUs), not open market purchases of common stock.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.